| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NANO-X IMAGING LTD$1.32
+0.03 (+2.31%)
Market Cap
128.05 M
EPS
-1.15
P/E Ratio
-
Value Trade
2.10 M
6.98 %
Week
-16.17 %
1 Month
-22.69 %
3 Month
-47.88 %
6 Month
-92.64 %
5 Year
-90.95 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
1.31 M
52 Week Range
1.59 - 5.72
% held by Insiders
0.37 %
% held by Institutions
25.68 %
Enterprise Value
76.29 M
Total Shares
65.38 M
Short %
12.33 %
Float Shares
64.20 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NNOX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NNOX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NNOXExclusive distribution agreement marks Nanox’s entry into the Peruvian market
Nanox Imaging Ltd. has signed an exclusive distribution agreement with Top Med SAC to deploy its Nanox.ARC system in Peru. The initial deployment will include six systems under a capex model, with Top Med responsible for regulatory approvals and support. This agreement aims to enhance access to diagnostic imaging services in Peru, addressing regional disparities.
Read more →NNOXNanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems
Nanox Imaging Ltd. has signed a distribution agreement with NuvioDx to enhance the deployment of its Nanox.ARC systems across the U.S. This partnership aims to expand access to advanced diagnostic imaging technologies. The Nanox.ARC system is noted for its cost-effectiveness and reduced radiation exposure compared to traditional methods.
Read more →NNOXNANO-X INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Nano-X Imaging Ltd. on Behalf of Nano-X Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Nano-X Imaging Ltd. on behalf of its stockholders regarding potential violations of federal securities laws and other unlawful practices. The investigation follows Nano-X's recent announcement of a $33.4 million loss for the fourth quarter of 2025 and a significant drop in share price of approximately 25%. Additionally, the departure of CFO Ran Daniel is part of the adverse news impacting the company. Investors affected by these developments are encouraged to reach out for legal guidance.
Read more →NNOXNanox Announces Fourth Quarter of 2025 Financial Results and provides Business Updates Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activit
Nanox Imaging Ltd. has announced its financial results for Q4 of 2025, revealing a net loss of $33.4 million, an increase from last year's loss of $14.1 million. The company is advancing its commercialization efforts in the U.S., having signed several distribution agreements for its Nanox.ARC systems. Additionally, Nanox has integrated Nanox Health IT and appointed a new CFO with significant experience, aiming for a seamless financial transition. Despite the operational progress, the significant losses and asset impairment have raised concerns about its fiscal health.
Read more →NNOXNanox Signs Distribution Agreement with Digital X-Ray Imaging to Expand Nanox.ARC Adoption in Arkansas
Nanox Imaging Ltd. has signed a distribution agreement with Digital X-Ray Imaging to promote the Nanox.ARC system in Arkansas. This partnership aims to enhance the adoption of advanced 3D imaging technology in various healthcare settings. The agreement marks the fourth such collaboration in 2026, reflecting Nanox's growing commercial momentum in the U.S. market.
Read more →NNOXNanox Signs Distribution Agreement with Imperial Imaging Technology to Expand Nanox.ARC Access Across U.S. Southeast
Nanox Imaging Ltd. has signed a distribution agreement with Imperial Imaging Technology to enhance the rollout of its Nanox.ARC imaging system across six southeastern U.S. states. This partnership aims to improve access to advanced musculoskeletal imaging in orthopedic practices, reducing patient travel and administrative burdens. The agreement aligns with Nanox's strategy to expand its distribution network in key markets.
Read more →NNOXNanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
Nanox Imaging Ltd. will debut its Nanox.ARC digital tomosynthesis system in Europe at ECR 2026, showcasing new AI capabilities. The system is designed for enhanced 3D imaging with lower costs and radiation doses. Live demonstrations and clinical data presentations will highlight its role in lung cancer screening and other applications. The event marks a significant step in Nanox's European market expansion.
Read more →NNOXNanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
Nanox Imaging Ltd. has received FDA 510(k) clearance for its TAP2D image enhancement capability, which allows radiologists to generate a 2D image from a tomosynthesis scan. This development aims to position Nanox's systems as primary diagnostic tools in the U.S. market, enhancing access to innovative medical imaging solutions. The new feature is designed to streamline workflow for healthcare professionals.
Read more →NNOXNanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
Nanox Imaging Ltd. has announced a collaboration with Adriamed to distribute its Nanox.ARC imaging system in Serbia, Montenegro, and Bosnia and Herzegovina. This partnership aims to enhance access to advanced medical imaging solutions in the Western Balkans, leveraging Adriamed's regional expertise. The Nanox.ARC system is CE Mark certified, allowing for commercialization across Europe.
Read more →NNOXNanox Announces $15 Million Registered Direct Offering of Common Stock
Nanox Imaging Ltd. has announced a registered direct offering of 3,826,530 ordinary shares, expected to raise approximately $15 million before expenses. The proceeds will primarily support working capital and general corporate purposes while bolstering the company's balance sheet. This move is aimed at advancing the company's technologies, market expansion, and AI infrastructure, as highlighted by CEO Erez Meltzer. The closing of the offering is scheduled for approximately November 25, 2025, pending customary conditions.
Read more →NNOXNanox Announces Third Quarter of 2025 Financial Results and Provides Business Update Management to host conference call and webcast Thursday, November 20 , 2025, at 8:30 AM ET Company advances commercialization and is on
Nanox Imaging Ltd (NASDAQ: NNOX) reported its third quarter 2025 financial results, showing a slight increase in net loss to $13.7 million from $13.6 million in Q3 2024. Revenue grew to $3.4 million, driven primarily by teleradiology services, which represented a strong performance with improved gross profit margins. Despite achieving some positive operational metrics, the company experienced significant cash burn, leading to negative cash flow of $30.4 million. Looking ahead, Nanox aims to deploy over 100 imaging systems worldwide by year-end 2025.
Read more →NNOXNanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions
Nanox Imaging Ltd. has announced its agreement to acquire VasoHealthcare IT from Vaso Corporation, a move aimed at accelerating the rollout of its AI solutions across U.S. healthcare facilities. This acquisition is expected to be finalized within weeks and will integrate VHC IT's proven operational support with Nanox.AI's technology. The deal includes a total consideration of up to $800,000, contingent upon performance metrics related to customer retention. Senior executives from both companies expressed optimism about the benefits of this transaction for their respective stakeholders and the healthcare sector as a whole.
Read more →NNOXNANO-X IMAGING LTD The Ofer Tech Park, 94 Shlomo Shmeltzer Road Petach Tikva, Israel 4970602 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
Nano-X Imaging Ltd has announced its Annual General Meeting of Shareholders scheduled for December 22, 2025, to be held at its offices in Petach Tikva, Israel. Shareholders of record as of November 24, 2025, will be entitled to vote at the meeting, which will also include discussions on the company's financial statements for the year ending December 31, 2024. Key items on the agenda include re-election of directors and re-appointment of accountants. Proxies must be submitted by December 21, 2025, at 11:59 p.m. EST.
Read more →NNOXNanox Announces First Quarter 2025 Financial Results and Provides Business Updates Management to host conference call and webcast on Thursday
Nanox Imaging Ltd (NASDAQ: NNOX) reported its financial results for the first quarter of 2025, revealing a net loss of $13.2 million compared to $12.2 million in the same quarter of 2024. The company noted progress in deploying its medical imaging solutions, with over 60 units in various stages of implementation. Additionally, the firm secured FDA clearance for its updated imaging system, which is aimed at improving patient access to imaging technology. Revenue from teleradiology services grew, contributing positively despite an overall increase in the net loss.
Read more →NNOXNanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and
Nanox Imaging Ltd has received FDA 510(k) clearance for its new imaging system, the Nanox.ARC X, intended for general use in producing tomographic images. This clearance was granted in less than 30 days post-submission, indicating efficient regulatory approval. The system features advanced imaging technology and is designed to fit in standard X-ray shielded rooms with minimal infrastructure requirements. Nanox plans to market the Nanox.ARC X alongside its existing products to enhance access to advanced medical imaging.
Read more →NNOXNanox Announces Fourth Quarter of 2024 Financial Results and provides Business Updates Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globa
Nanox Imaging Ltd (NASDAQ: NNOX) reported its financial results for Q4 2024, highlighting notable regulatory achievements including FDA general use clearance and a CE Mark in the EU. The company experienced an increase in net losses, reporting a $14.1 million loss compared to $10.2 million from the previous year, despite revenue growth attributed to teleradiology services. Management remains optimistic about the future, citing successful navigation of regulatory hurdles and the signing of new partnerships as essential for advancing their commercial efforts in the medical imaging sector.
Read more →NNOXNanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general
Nanox Imaging Ltd. has announced that its Nanox.ARC Imaging System has received CE mark certification, enabling its commercial distribution in the European market. This certification follows previous FDA clearance, signifying a crucial step in the company's global expansion strategy. The Nanox.ARC system offers advanced imaging capabilities with a focus on providing better diagnostic tools while reducing radiation exposure compared to traditional methods. As Nanox prepares for broader deployment, the company emphasizes its intention to integrate its technology into healthcare workflows effectively.
Read more →NNOXNanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdomi
Nanox Imaging Ltd. announced that its Nanox.ARC Imaging System has received 510(k) clearance from the FDA for general use, which includes applications in pulmonary and other indications. The company asserts that this clearance will expand its commercial footprint in the U.S. healthcare market. The Nanox.ARC system leverages advanced digital X-ray technology and tomosynthesis to enhance imaging services. Despite the positive developments, Nanox faces potential risks related to market acceptance, compliance, and geopolitical uncertainties.
Read more →NNOXNanox Announces Third Quarter of 2024 Financial Results and Provides Business Update Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key
Nanox Imaging Ltd (NASDAQ: NNOX) announced its financial results for the third quarter of 2024, reporting a net loss of $13.6 million, improved from a loss of $21.4 million in the same period last year. The company achieved revenue growth, with $3.0 million reported, primarily from teleradiology services and AI solutions, despite high gross loss margins. Management remains optimistic about the deployment of its imaging solutions and regulatory progress in the U.S. and Europe. The expansion of its U.S. sales and support teams aligns with its goals for growth into 2025 and beyond.
Read more →NNOXNANO-X IMAGING LTD The Ofer Tech Park, 94 Shlomo Shmeltzer Road Petach Tikva, Israel 4970602 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 3, 2024 Dear Shareholders: We cordially invite y
Nano-X Imaging Ltd has announced its upcoming Annual General Meeting of Shareholders scheduled for December 3, 2024, at its offices in Israel. The agenda includes the re-election of directors Erez Meltzer and Nehama Ronen, approval of compensation terms for non-executive directors, and the re-appointment of Kesselman & Kesselman as auditors. Shareholders recorded by November 4, 2024, can attend the meeting to vote on these proposals and discuss the company's financial results for the year ending December 31, 2023.
Read more →NNOXNanox Announces Second Quarter of 2024 Financial Results and Provides Business Update Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications
Nanox Imaging Ltd. announced its financial results for Q2 2024, reporting a net loss decrease to $13.6 million from $17.4 million the previous year. The company highlighted its progress in deploying the Nanox ARC system in the US market and received FDA clearance for its upgraded AI cardiac solution, HealthCCSng V 2.0. While revenue rose slightly to $2.7 million, the company faced challenges with a gross loss margin that increased to 106%. Despite these issues, the firm remains committed to expanding its commercial infrastructure and enhancing medical imaging accessibility globally.
Read more →NNOXNanox Announces First Quarter of 2024 Financial Results and Provides Business Update Accelerates Deployment of Nanox.ARC in United States signed two commercial agreements for Nanox.AI Management to host conference call a
Nanox Imaging Ltd. has announced its financial results for the first quarter of 2024, highlighting revenue growth to $2.6 million and new commercial agreements for its Nanox.AI product suite. Despite the positive developments, the company reported a net loss of $12.2 million, slightly increased from $11.8 million over the same period last year. Additionally, the gross loss margin saw a significant decline, although legal expenses decreased due to the resolution of an SEC investigation. The company is focused on expanding its technology's deployment and optimizing operations in the U.S. market.
Read more →NNOXNanox Files 2023 Annual Report on Form 20-F PETACH TIKVA, Israel--(BUSINESS WIRE)
Nanox Imaging Ltd (NNOX) has filed its 2023 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. This report contains the company's audited consolidated financial statements for the fiscal year ending December 31, 2023. Nanox focuses on utilizing its proprietary medical imaging technology to improve accessibility and affordability in diagnostic medicine globally. The report can be accessed through the SEC and Nanox's official website, with hard copies available upon request.
Read more →NNOXNanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging Manage
Nanox Imaging Ltd. reported its financial results for the fourth quarter of 2023, highlighting significant progress with the launch of its FDA-cleared Nanox.ARC systems in the U.S., marking a pivotal advancement in medical imaging. The company achieved a net loss reduction to $10.2 million, down from $52.8 million a year prior, partly due to resolved legal issues. Revenue was up slightly to $2.4 million, driven primarily by teleradiology services. However, challenges persist with operational costs affecting profitability.
Read more →NNOXNanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver Nanox's HealthFLD is pioneering the use of a fully automated AI software for liver attenuation
Nanox has received FDA clearance for HealthFLD, an advanced AI software designed to assist clinicians in assessing fatty liver through automated analysis of CT scans. This marks the third product in Nanox's AI healthcare solutions aimed at improving detection capabilities related to metabolic dysfunction-associated steatotic liver disease (MASLD). The software provides a non-invasive method to identify liver steatosis, which is crucial given the rising prevalence of obesity and related health issues. HealthFLD is expected to streamline the diagnosis process, enhancing early intervention and potential treatment pathways.
Read more →NNOXNanox Mourns Death of Its Founder, Ran Poliakine
Nanox Imaging Ltd announced the death of its founder Ran Poliakine on January 12, 2024. Over his 35-year career, Poliakine founded more than 20 companies and obtained over 70 patents across various fields. He played a key role in developing Nanox's medical imaging technologies aimed at making diagnostic medicine more accessible. Following his death, the board is set to appoint a new Chair, marking a pivotal transition for the company as it continues to pursue his vision.
Read more →NNOXNanox Announces Third Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equi
Nanox Imaging Ltd. reported its third quarter financial results for 2023 with a slight revenue increase to $2.5 million but a net loss of $21.4 million. The company noted significant progress in its commercialization efforts, including the deployment of the Nanox.ARC system in a commercial imaging center in New Jersey and a manufacturing agreement with Varex Imaging. However, total operating losses increased, primarily due to a goodwill impairment and rising sales and marketing expenses as they prepare for market entry in the U.S. Revenue from teleradiology services saw a decline, attributed to customer attrition.
Read more →NNOXNANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
Nano-X Imaging Ltd is set to hold its Annual General Meeting of Shareholders on December 27, 2023, in Neve Ilan, Israel. Shareholders will vote on key proposals, including the re-election of several directors and the appointment of an independent accounting firm. Attendees can interact with management regarding the company's financial performance and future direction. Voting instructions have been detailed for shareholders, emphasizing the importance of their participation.
Read more →NNOXNanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging System NEVE ILAN, Israel and
Nanox has entered into a strategic manufacturing agreement with Varex Imaging Corporation to enhance its Nanox.ARC medical imaging system. The collaboration aims to utilize Varex's X-ray tubes, making use of Nanox's innovative digital X-ray source technology. This partnership supports Nanox's vision of improving healthcare accessibility through advanced imaging solutions while also lowering production costs compared to traditional methods. The agreement further reinforces Nanox's commitment to commercialization and expansion of its medical imaging technology.
Read more →NNOXNanox Announces Second Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash
Nanox Imaging Ltd. (NNOX) announced its financial results for Q2 2023, highlighting a revenue increase to $2.6 million and improved net loss of $17.4 million compared to $19.6 million in Q2 2022. The company received FDA 510(k) clearance for its Nanox.ARC imaging system and is progressing with partnerships to secure components for its supply chain. Despite these achievements, Nanox still faces challenges, including high net losses and expenses related to an ongoing SEC investigation.
Read more →NNOXNANOX ANNOUNCES $30
Nanox Imaging Ltd (NASDAQ: NNOX) has announced a $30 million securities purchase agreement with institutional investors for the sale of 2,142,857 ordinary shares and associated warrants. The funds raised will support the development of their medical imaging products, including the Nanox.ARC and Nanox.CLOUD systems. The offering is scheduled for closure around July 26, 2023, pending customary conditions. While this financing provides necessary capital, it may also lead to share dilution for current investors.
Read more →NNOXNanox Announces First Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the first quarter of 2023 with cash, cash equivalents, restricted cash a
Nanox Imaging Ltd (NASDAQ: NNOX) reported its financial results for the first quarter of 2023, highlighting key developments, including FDA clearance for its Nanox.ARC imaging system. The company achieved revenue of $2.4 million, an increase from the prior year's $1.8 million, aided by successful efforts in teleradiology services. Despite this growth, Nanox reported a net loss of $11.8 million, though it was an improvement compared to the previous year. The company is also advancing its global presence through a new distribution agreement in Morocco and establishing a demo center in Florida.
Read more →NNOXNanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging - Nanox.ARC presents high powered digital X-ray tubes for 3D tomosynthesis imaging - Nanox.ARC could help expand the availability o
Nanox Imaging Ltd (NNOX) has received FDA 510(k) clearance for its innovative imaging system, Nanox.ARC, which features advanced digital X-ray technology for 3D tomosynthesis. This approval marks a significant step in enhancing access to medical imaging, particularly in underserved regions. The system is designed to produce detailed tomographic images, potentially revolutionizing healthcare delivery and enabling early disease detection. Following this clearance, Nanox aims to pursue further regulatory approvals and expand clinical use globally.
Read more →NNOXNanox Files 2022 Annual Report on Form 20-F NEVE ILAN, Israel--(BUSINESS WIRE)
Nanox Imaging Ltd. has filed its annual report on Form 20-F with the SEC for the fiscal year ending December 31, 2022. The report, accessible on both the SEC and Nanox's websites, includes audited financial statements and outlines the company's vision for advancing diagnostic medicine. The company emphasizes the importance of its proprietary medical imaging technology, which aims to enhance efficiency and reduce costs in healthcare. However, the report also highlights several risks that could impact the realization of its business prospects and technological advancements.
Read more →NNOXNanox Announces Fourth Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the fourth quarter of 2022 with cash, cash equivalents and marketable secu
Nanox Imaging Ltd announced its fourth quarter 2022 financial results, revealing a revenue of $2.1 million, a decrease from $2.4 million in the previous quarter. The company reported a considerable net loss of $44.8 million, substantially higher than the same period last year, largely due to goodwill impairment. Despite these challenges, Nanox noted progress in deploying its imaging technology and a collaboration with Nuance to enhance its market presence. The company ended the quarter with substantial cash reserves of $102.9 million.
Read more →NNOXNanox to Report Fourth Quarter 2022 Financial Results on
Nanox Imaging Ltd (NASDAQ: NNOX) is set to report its fourth-quarter 2022 financial results on March 9, 2023. CEO Erez Meltzer and CFO Ran Daniel will lead a conference call to discuss these results and provide a business update. The company aims to leverage its proprietary medical imaging technology to enhance global accessibility to diagnostic medicine, which is central to their mission of improving early detection and treatment of medical conditions. However, the company also faces significant risks related to technology development, regulatory compliance, and market acceptance.
Read more →NNOXNanox.AI Connects to Nuance Precision Imaging Network to Improve Early Detection of Chronic Diseases with Workflow-Integrated AI The secure nationwide AI-powered cloud platform streamlines care team communication and del
Nanox.AI has established a connection with the Nuance Precision Imaging Network, leveraging AI-powered analytics to enhance early detection of chronic diseases within clinical workflows. This collaboration aims to improve healthcare outcomes and reduce costs by facilitating communication among care teams and enabling the extraction of actionable insights from diagnostic imaging. Both companies emphasize the importance of predictive medicine in addressing rising rates of chronic illnesses. Nanox.AI's technology is particularly focused on identifying conditions such as osteoporosis and cardiovascular disease.
Read more →NNOXNanox Announces Third Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the third quarter of 2022 with cash, cash equivalents and marketable securi
Nanox Announces Third Quarter 2022 Financial Provides Business Update Reports progress towards global supply chain Ended the third quarter of 2022 with cash, cash equivalents and marketable securities of $117.1 million Management to host conference call and webcast Thursday
Read more →NNOXNanox Announces Second Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the second quarter of 2022 with cash, cash equivalents and marketable secu
Nanox Announces Second Quarter 2022 Financial Provides Business Update Reports progress towards global supply chain Ended the second quarter of 2022 with cash, cash equivalents and marketable securities of $126.7 million Management to host conference call and webcast today,
Read more →NNOXNanox Announces its First Quarter of 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the first quarter of 2022 with cash and marketable securities of $13
Nanox Announces its First Quarter of 2022 Financial Provides Business Update Reports progress towards global supply chain Ended the first quarter of 2022 with cash and marketable securities of $139.5 million Management to host conference call and webcast today, May 19, 2022
Read more →NNOXNanox Opens South Korean Fabrication Plant to Produce Semiconductor Chips for Novel Digital Nanox.ARC 3D X-ray System Fully operational facility will produce Nanox.SOURCE chip, the core innovative component of Nanox.ARC,
Nanox Opens South Korean Fabrication Plant to Produce Semiconductor Chips for Novel Digital Nanox.ARC 3D X-ray System Fully operational facility will produce Nanox.SOURCE chip, the core innovative component of Nanox.ARC, which has potential to bring X-ray technology to two-th
Read more →NNOXNanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update Management to host conference call and webcast today, March 31, at 8:30
Nanox Announces Fourth Quarter 2021 Financial Provides Business Update Management to host conference call and webcast today, March 31, at 8:30 AM ET NEVE ILAN, Israel-March 31, 2022 -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imagin
Read more →NNOXNANO-X DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) in the United States D
Read more →NNOXNANO-X ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) in the United States D
Read more →NNOXNanox Announces Third Quarter 2021 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the third quarter with cash and marketable securities of $180.3 million Man
Nanox Announces Third Quarter 2021 Financial Provides Business Update Reports progress towards global supply chain Ended the third quarter with cash and marketable securities of $180.3 million Management to host conference call and webcast today, November 17, at 8:30 AM ET
Read more →NNOXNANO-X IMAGING LTD. CLASS ACTION REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Nano-X Imaging Ltd.
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit on behalf of purchasers or acquirers of Nano-X Imaging Ltd. (NASDAQ:NNOX) (“Nano-X”) securities between June 17, 2021 and August 18, 2021
Read more →NNOXNANO-X IMAGING LTD. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Nano-X Imaging Ltd.
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit on behalf of purchasers or acquirers of Nano-X Imaging Ltd. (NASDAQ:NNOX) (“Nano-X”) securities between June 17, 2021 and August 18, 2021
Read more →NNOXNANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 5360360 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 4, 2021 To our Shareholders: You are invited to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd ("we" or the "Company") to be held at the Company's offices at The Communications Center, N
Read more →NNOXNanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc. with the Goal of Creating an Integrated, Globally Connected En
Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc. with the Goal of Creating an Integrated, Globally Connected End-to-End Radiology Solution and Population Preventive Heal
Read more →NNOXNanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria Making its first steps in West Africa, Nanox partners with EiLEENO Pharma to make medical imaging accessible and available across Nigeria t
Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria Making its first steps in West Africa, Nanox partners with EiLEENO Pharma to make medical imaging accessible and available across Nigeria to both public and private medical institutions Neve Ilan
Read more →NNOXNanox Announces FDA 510(k) Submission for First Version of Multi-Source Nanox.ARC 510(K) Class II FDA submission seeks clearance of the first version of company's multi-source 3-D digital tomosynthesis system as the next
Nanox Announces FDA 510(k) Submission for First Version of Multi-Source Nanox.ARC 510(K) Class II FDA submission seeks clearance of the first version of company's multi-source 3-D digital tomosynthesis system as the next step in its U.S. NEVE ILAN, Israel - June 17, 2021 -- N
Read more →NNOXNanox Announces First Quarter 2021 Results and Provides Business Update Announced FDA 510(k) clearance for the single source Nanox Cart X-Ray System Scaling up Company's semiconductor fabrication plant in South Korea End
Nanox Announces First Quarter 2021 Results and Provides Business Update Announced FDA 510(k) clearance for the single source Nanox Cart X-Ray System Scaling up Company's semiconductor fabrication plant in South Korea Ended Q1 with cash and cash equivalents of $219 Manageme
Read more →NNOXNANO-X IMAGING LTD Files 2020 Annual Report on Form 20-F
NEVE ILAN, Israel, April 06, 2021 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (www.nanox.vision) (“Nanox” or the “Company”), the innovative medical imaging technology company democratizing healthcare, today announced that it has filed its annual report on Form 20-F for
Read more →NNOXNanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray
Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray NEVE ILAN, Israel - April 2, 2021 -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today that its single-source Nanox.
Read more →NNOXNanox Announces Fourth Quarter 2020 Results and Provides Business Update Successfully demonstrates the Nanox.ARC in range of 2D and 3D imaging applications at the 2020 Radiology Society of North America (RSNA) Virtual An
Nanox Announces Fourth Quarter 2020 Results Provides Business Update Successfully demonstrates the Nanox.ARC in range of 2D and 3D imaging applications at the 2020 Radiology Society of North America (RSNA) Virtual Annual Meeting Continues to build out commercial and manufact
Read more →NNOXNano-X Imaging Ltd The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 536 0360 NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 536 0360 NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS To Be Held on February 9, 2021 To our Shareholders: You are invited to attend a Special Meeting of Shareholders of Nano-X Imaging Ltd ("we" or the
Read more →NNOXNano-X Imaging, Ltd. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
Investors with losses are encouraged to contact the firm before November 16, 2020; click here to submit trade information LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Nano-X Imaging,
Read more →NNOXNanox Announces Third Quarter 2020 Results and Provides Business Update On track to obtain 510(k) clearance for multi-source Nanox.ARC by mid-year 2021 Signs agreement with SPI Medical for deployment of 630 Nanox.ARC uni
Nanox Announces Third Quarter 2020 Results and Provides Business Update On track to obtain 510(k) clearance for multi-source Nanox.ARC by mid-year 2021 Signs agreement with SPI Medical for deployment of 630 Nanox.ARC units across Mexico and Guatemala; brings total contracted d
Read more →NNOXNano-X Imaging, Ltd.: Portnoy Law Advises Last Days to Participate Actively in the Class Action Lawsuit
Investors are encouraged to contact the firm before November 16, 2020; click here to submit trade information LOS ANGELES, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Nano-X Imaging, Ltd. (NASDA
Read more →NNOXNANO-X IMAGING LTD Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
PHILADELPHIA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) to determine whether the Company engaged in securities fraud or other unlawf
Read more →NNOXDawn of early detection healthcare Investor PresentationSeptember 2020 1 Disclaimers Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or t
Dawn of early detection healthcare Investor PresentationSeptember 2020 1 Disclaimers Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of
Read more →NNOXNANO-X ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm
NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of investors that
Read more →NNOXNanox Issues Statement on Unusual Trading Activities NEVE ILAN, Israel
Nanox Issues Statement on Unusual Trading Activities NEVE ILAN, Israel-- September 16, 2020 -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today issued a statement in response to unusual trading activities that
Read more →NNOXNANO-X IMAGING ALERT: Bragar Eagel & Squire, P.C. is Investigating Nano-X Imaging Ltd. on Behalf of Nano-X Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Nano-X Imaging Ltd. (NASDAQ: NNOX) on behalf of Nano-X stockholders. Our investigation concerns whether Nano-X
Read more →NNOXNanox S igns A greement with SPI Medical for the D eployment of 630 Nanox.ARC U nits in Mexico Subject to regulatory approval and acceptance test, the agreement guarantees minimum service fees of $119 million to Nanox ov
Nanox Signs Agreement with SPI Medical for the Deployment of 630 Nanox.ARC Units in Mexico Subject to regulatory approval and acceptance test, the agreement guarantees minimum service fees of $119 million to Nanox over seven years aiming to service both public and private sect
Read more →Competitive Position
How NNOX ranks across every disease it competes inCompetitive Position is a premium feature
See how NNOX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial